Gansu Longshenrongfa Pharmaceutical Industry Co (SZSE:300534) EBIT : ¥97 Mil (TTM As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Gansu Longshenrongfa Pharmaceutical Industry Co EBIT?

Gansu Longshenrongfa Pharmaceutical Industry Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ¥16 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥97 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Gansu Longshenrongfa Pharmaceutical Industry Co's annualized ROC % for the quarter that ended in Sep. 2024 was 5.57%. Gansu Longshenrongfa Pharmaceutical Industry Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 13.97%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Gansu Longshenrongfa Pharmaceutical Industry Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 3.71%.

Gansu Longshenrongfa Pharmaceutical Industry Co EBIT Historical Data

The historical data trend for Gansu Longshenrongfa Pharmaceutical Industry Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gansu Longshenrongfa Pharmaceutical Industry Co EBIT Chart

Gansu Longshenrongfa Pharmaceutical Industry Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

20.77

5.88

-4.21

66.14

100.97

Gansu Longshenrongfa Pharmaceutical Industry Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial															21.49	23.82	37.41	20.08	15.60

Competitive Comparison of Gansu Longshenrongfa Pharmaceutical Industry Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Gansu Longshenrongfa Pharmaceutical Industry Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gansu Longshenrongfa Pharmaceutical Industry Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gansu Longshenrongfa Pharmaceutical Industry Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Gansu Longshenrongfa Pharmaceutical Industry Co's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Gansu Longshenrongfa Pharmaceutical Industry Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥97 Mil.

Gansu Longshenrongfa Pharmaceutical Industry Co (SZSE:300534) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Gansu Longshenrongfa Pharmaceutical Industry Co's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	57.144 * ( 1 - 29.07% )	/	( (728.796	+	726.537)	/ 2 )
=	40.5322392	/	727.6665
=	5.57 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1372.758	-	479.675	-	( 352.993	-	max(0, 508.715	-	673.002	+	352.993	))
=	728.796

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1373.001	-	497.305	-	( 315.739	-	max(0, 513.523	-	662.682	+	315.739	))
=	726.537

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Gansu Longshenrongfa Pharmaceutical Industry Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	62.416	/	( ( (447.244 + max(-192.179, 0))	+	(446.439 + max(-173.261, 0)) )	/	2 )
=	62.416	/	( ( 447.244	+	446.439 )	/	2 )
=	62.416	/	446.8415
=	13.97 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(184.164	+	101.432	+	26.501)	-	(479.675	+	0	+	24.601)
=	-192.179

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(202.348	+	107.804	+	28.916)	-	(497.305	+	0	+	15.024)
=	-173.261

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Gansu Longshenrongfa Pharmaceutical Industry Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	96.916	/	2614.949
	=	3.71 %

Gansu Longshenrongfa Pharmaceutical Industry Co EBIT Related Terms

Thank you for viewing the detailed overview of Gansu Longshenrongfa Pharmaceutical Industry Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Gansu Longshenrongfa Pharmaceutical Industry Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (SZSE:300534) » Definitions » EBIT

Traded in Other Exchanges

N/A

Address

No. 10, Guofang Road, Dingyuan Town, Yuzhong County, Gansu Province, Lanzhou, CHN, 730102

Website

https://www.lsrfzy.com

Gansu Longshenrongfa Pharmaceutical Industry Co Ltd is mainly engaged in the pharmaceutical business. It is engaged in the research and development of new drugs, traditional Chinese medicine processing and production. Its products portfolio includes Yuan Hu Zhitong Dripping Pills, Qiwei Wenyang Capsule and Xiaoshuan Tongluo Tablets. Its products are used to adjust gas, promote blood circulation, relieve pain, relieve cough, eliminate phlegm, relieve asthma, clear heat and dispel dampness, among others.

Executives

Chen Yao Wu	Executives
Zhang Jin De	Director
Zhang Fan	Executives
Kong Jian Feng	Executives
Yue Qing Xin	Supervisors
Kang Yong Hong	Executives

Gansu Longshenrongfa Pharmaceutical Industry Co Headlines

No Headlines